

Ian Law

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2224420/publications.pdf>

Version: 2024-02-01

102
papers

4,374
citations

117625

34
h-index

118850

62
g-index

114
all docs

114
docs citations

114
times ranked

4968
citing authors

#	ARTICLE	IF	CITATIONS
1	Proposal of a new grading system for meningioma resection: the Copenhagen Protocol. <i>Acta Neurochirurgica</i> , 2022, 164, 229-238.	1.7	14
2	Case 24: Progressive Glioma. , 2022, , 119-123.		0
3	Letter to the Editor. Copenhagen grading of meningioma. <i>Journal of Neurosurgery</i> , 2022, 136, 1506-1508.	1.6	2
4	EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 632-651.	6.4	82
5	Joint EANM/SIOPE/RAPNO practice guidelines/SNMMI procedure standards for imaging of paediatric gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3852-3869.	6.4	14
6	Investigational PET tracers in neuro-oncology—What’s on the horizon? A report of the PET/RANO group. <i>Neuro-Oncology</i> , 2022, 24, 1815-1826.	1.2	14
7	Prevalence of cognitive impairment and its relation to mental health in Danish lymphoma survivors. <i>Supportive Care in Cancer</i> , 2021, 29, 3319-3328.	2.2	5
8	Somatostatin Receptor—Targeted Radiopeptide Therapy in Treatment-Refractory Meningioma: Individual Patient Data Meta-analysis. <i>Journal of Nuclear Medicine</i> , 2021, 62, 507-513.	5.0	37
9	Improved Detection of Postoperative Residual Meningioma with [68Ga]Ga-DOTA-TOC PET Imaging Using a High-resolution Research Tomograph PET Scanner. <i>Clinical Cancer Research</i> , 2021, 27, 2216-2225.	7.0	10
10	Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group. <i>Neuro-Oncology</i> , 2021, 23, 881-893.	1.2	75
11	Comparison of the clinical impact of 2-[18F]FDG-PET and cerebrospinal fluid biomarkers in patients suspected of Alzheimer’s disease. <i>PLoS ONE</i> , 2021, 16, e0248413.	2.5	5
12	Finding our way through the labyrinth of dementia biomarkers. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2320-2324.	6.4	5
13	Diagnostic accuracy and clinical impact of [18F]FET PET in childhood CNS tumors. <i>Neuro-Oncology</i> , 2021, 23, 2107-2116.	1.2	11
14	Validation of kinetic modeling of [15O]H ₂ O PET using an image derived input function on hybrid PET/MRI. <i>NeuroImage</i> , 2021, 233, 117950.	4.2	12
15	Regional and interindividual relationships between cerebral perfusion and oxygen metabolism. <i>Journal of Applied Physiology</i> , 2021, 130, 1836-1847.	2.5	6
16	Hybrid 2-[18F] FDG PET/MRI in premanifest Huntington’s disease gene-expansion carriers: The significance of partial volume correction. <i>PLoS ONE</i> , 2021, 16, e0252683.	2.5	10
17	Novel Homozygous Truncating Variant Widens the Spectrum of Early-Onset Multisystemic SYNE1 Ataxia. <i>Cerebellum</i> , 2021, , 1.	2.5	0
18	Deep-learning-based attenuation correction in dynamic [¹⁵ O]H ₂ O studies using PET/MRI in healthy volunteers. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 3314-3323.	4.3	4

#	ARTICLE	IF	CITATIONS
19	PET Imaging in Neurodegeneration and Neuro-oncology: Variants and Pitfalls. <i>Seminars in Nuclear Medicine</i> , 2021, 51, 408-418.	4.6	15
20	Comparison of simultaneous arterial spin labeling MRI and ¹⁵ O-H ₂ O PET measurements of regional cerebral blood flow in rest and altered perfusion states. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020, 40, 1621-1633.	4.3	42
21	Validation of diffuse correlation spectroscopy against ¹⁵ O-water PET for regional cerebral blood flow measurement in neonatal piglets. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020, 40, 2055-2065.	4.3	33
22	A visual rating scale for cingulate island sign on ¹⁸ F-FDG-PET to differentiate dementia with Lewy bodies and Alzheimer's disease. <i>Journal of the Neurological Sciences</i> , 2020, 410, 116645.	0.6	15
23	AI-driven attenuation correction for brain PET/MRI: Clinical evaluation of a dementia cohort and importance of the training group size. <i>NeuroImage</i> , 2020, 222, 117221.	4.2	47
24	Amyloid-PET and ¹⁸ F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. <i>Lancet Neurology</i> , The, 2020, 19, 951-962.	10.2	254
25	Mania triggered by levodopa treatment in a patient with frontotemporal dementia caused by A C9orf72 repeat expansion: A case report. <i>Clinical Neurology and Neurosurgery</i> , 2020, 198, 106147.	1.4	3
26	Effect of blood glucose and body weight on image quality in brain [¹⁸ F]FDG PET imaging. <i>Nuclear Medicine Communications</i> , 2020, 41, 1265-1274.	1.1	3
27	COVID-19 and the brain: impact on nuclear medicine in neurology. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2487-2492.	6.4	18
28	PET imaging of meningioma with ¹⁸ F-FLT: a predictor of tumour progression. <i>Brain</i> , 2020, 143, 3308-3317.	7.6	11
29	Evaluating ² -[¹⁸ F]FDG-PET in differential diagnosis of dementia using a data-driven decision model. <i>NeuroImage: Clinical</i> , 2020, 27, 102267.	2.7	9
30	EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1885-1912.	6.4	134
31	Pharmacokinetic analysis of [⁶⁸ Ga]Ga-DOTA-TOC PET in meningiomas for assessment of in vivo somatostatin receptor subtype 2. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2577-2588.	6.4	10
32	Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification: an individual patient data meta-analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 378-387.	1.9	75
33	In vivo imaging of cell proliferation in meningioma using ³ -deoxy- ³ -[¹⁸ F]fluorothymidine PET/MRI. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1496-1509.	6.4	9
34	Prognostic value of complementary biomarkers of neurodegeneration in a mixed memory clinic cohort. <i>PeerJ</i> , 2020, 8, e9498.	2.0	5
35	Recurrent glioblastoma versus late posttreatment changes: diagnostic accuracy of O-(2-[¹⁸ F]fluoroethyl)-L-tyrosine positron emission tomography (¹⁸ F-FET PET). <i>Neuro-Oncology</i> , 2019, 21, 1595-1606.	1.2	37
36	Early Postoperative ¹⁸ F-FET PET/MRI for Pediatric Brain and Spinal Cord Tumors. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1053-1058.	5.0	29

#	ARTICLE	IF	CITATIONS
37	Markerless motion tracking and correction for PET, MRI, and simultaneous PET/MRI. PLoS ONE, 2019, 14, e0215524.	2.5	31
38	Moderate- to high-intensity exercise does not modify cortical β -amyloid in Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 208-215.	3.7	20
39	Hybrid FDG PET/MRI vs. FDG PET and CT in patients with suspected dementia – A comparison of diagnostic yield and propagated influence on clinical diagnosis and patient management. PLoS ONE, 2019, 14, e0216409.	2.5	16
40	A modality-adaptive method for segmenting brain tumors and organs-at-risk in radiation therapy planning. Medical Image Analysis, 2019, 54, 220-237.	11.6	31
41	MNGI-13. DYNAMIC IMAGING OF MENINGIOMA WITH ^3H -DEOXY- ^3H -[18F]-FLUOROTHYIMIDINE USING POSITRON EMISSION TOMOGRAPHY: A POSSIBLE PREDICTOR OF TUMOR GROWTH. Neuro-Oncology, 2019, 21, vi142-vi142.	1.2	0
42	Phase contrast mapping MRI measurements of global cerebral blood flow across different perfusion states – A direct comparison with ^{15}O - ^2O positron emission tomography using a hybrid PET/MR system. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 2368-2378.	4.3	17
43	PET imaging in patients with brain metastasis – report of the RANO/PET group. Neuro-Oncology, 2019, 21, 585-595.	1.2	139
44	Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 540-557.	6.4	348
45	Feasibility of multi-parametric PET and MRI for prediction of tumour recurrence in patients with glioblastoma. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 603-613.	6.4	44
46	Hybrid PET/MRI imaging in healthy unsedated newborn infants with quantitative rCBF measurements using ^{15}O -water PET. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 782-793.	4.3	15
47	Adoptive cancer immunotherapy using DNA-demethylated T helper cells as antigen-presenting cells. Nature Communications, 2018, 9, 785.	12.8	29
48	Beneficial effect of intravenous immunoglobulin treatment in a patient with antiphospholipid syndrome associated chorea. Journal of the Neurological Sciences, 2018, 390, 52-53.	0.6	2
49	Non-invasive kinetic modelling of PET tracers with radiometabolites using a constrained simultaneous estimation method: evaluation with ^{11}C -SB201745. EJNMMI Research, 2018, 8, 58.	2.5	17
50	NIMG-53. REPEATABILITY OF O-(2-18F-FLUOROETHYL)-L-TYROSINE POSITRON EMISSION TOMOGRAPHY (FET-PET) SCANNING AND THE INFLUENCE OF PROTEIN INTAKE IN GLIOMA. Neuro-Oncology, 2018, 20, vi188-vi188.	1.2	0
51	Components of day-to-day variability of cerebral perfusion measurements – Analysis of phase contrast mapping magnetic resonance imaging measurements in healthy volunteers. PLoS ONE, 2018, 13, e0197807.	2.5	6
52	RADI-13. EXPERIENCE WITH 18F-FET PET/MRI FOR CNS-TUMORS IN CHILDREN AND ADOLESCENTS. Neuro-Oncology, 2018, 20, i172-i172.	1.2	1
53	No evidence for direct effects of recombinant human erythropoietin on cerebral blood flow and metabolism in healthy humans. Journal of Applied Physiology, 2018, 124, 1107-1116.	2.5	3
54	Interindividual and regional relationship between cerebral blood flow and glucose metabolism in the resting brain. Journal of Applied Physiology, 2018, 125, 1080-1089.	2.5	16

#	ARTICLE	IF	CITATIONS
55	Early treatment response evaluation using FET PET compared to MRI in glioblastoma patients at first progression treated with bevacizumab plus lomustine. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2377-2386.	6.4	45
56	Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1509-1525.	6.4	81
57	Deep Learning Based Attenuation Correction of PET/MRI in Pediatric Brain Tumor Patients: Evaluation in a Clinical Setting. <i>Frontiers in Neuroscience</i> , 2018, 12, 1005.	2.8	78
58	Role of amino-acid PET in high-grade gliomas: limitations and perspectives. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 62, 254-266.	0.7	16
59	Estimation of an image derived input function with MR-defined carotid arteries in FDG-PET human studies using a novel partial volume correction method. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 1398-1409.	4.3	48
60	SCA28: Novel Mutation in the AFG3L2 Proteolytic Domain Causes a Mild Cerebellar Syndrome with Selective Type-1 Muscle Fiber Atrophy. <i>Cerebellum</i> , 2017, 16, 62-67.	2.5	16
61	Patterns of failure for patients with glioblastoma following O-(2-[¹⁸ F]fluoroethyl)-L-tyrosine PET- and MRI-guided radiotherapy. <i>Radiotherapy and Oncology</i> , 2017, 122, 380-386.	0.6	30
62	The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy. <i>NeuroImage: Clinical</i> , 2017, 13, 386-394.	2.7	101
63	The effect of alternate-day caloric restriction on the metabolic consequences of 8 days of bed rest in healthy lean men: a randomized trial. <i>Journal of Applied Physiology</i> , 2017, 122, 230-241.	2.5	22
64	PET imaging in patients with meningioma—report of the RANO/PET Group. <i>Neuro-Oncology</i> , 2017, 19, 1576-1587.	1.2	157
65	A multi-centre evaluation of eleven clinically feasible brain PET/MRI attenuation correction techniques using a large cohort of patients. <i>NeuroImage</i> , 2017, 147, 346-359.	4.2	200
66	The need of standardization and of large clinical studies in an emerging indication of [¹⁸ F]FDG PET: the autoimmune encephalitis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 353-357.	6.4	44
67	Toxicity and efficacy of re-irradiation of high-grade glioma in a phase I dose- and volume escalation trial. <i>Radiotherapy and Oncology</i> , 2017, 125, 223-227.	0.6	21
68	The D313Y variant in the <i>GLA</i> gene—no evidence of a pathogenic role in Fabry disease. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2017, 77, 617-621.	1.2	19
69	Comparison of analytical methods of brain [¹⁸ F]FDG-PET after severe traumatic brain injury. <i>Journal of Neuroscience Methods</i> , 2017, 291, 176-181.	2.5	8
70	The prognostic value of FET PET at radiotherapy planning in newly diagnosed glioblastoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 373-381.	6.4	54
71	Clinical PET/MRI in neurooncology: opportunities and challenges from a single-institution perspective. <i>Clinical and Translational Imaging</i> , 2017, 5, 135-149.	2.1	47
72	Comparison of global cerebral blood flow measured by phase-contrast mapping MRI with ¹⁵ O- ² O positron emission tomography. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 45, 692-699.	3.4	41

#	ARTICLE	IF	CITATIONS
73	RESOLUTE PET/MRI Attenuation Correction for O-(2-18F-fluoroethyl)-L-tyrosine (FET) in Brain Tumor Patients with Metal Implants. <i>Frontiers in Neuroscience</i> , 2017, 11, 453.	2.8	27
74	Presentation of Two Cases with Early Extracranial Metastases from Glioblastoma and Review of the Literature. <i>Case Reports in Oncological Medicine</i> , 2016, 2016, 1-5.	0.3	14
75	RA-07FEASIBILITY OF EARLY POSTOPERATIVE18F-FET PET/MRI AFTER SURGERY FOR BRAIN TUMOR IN PEDIATRIC PATIENTS. <i>Neuro-Oncology</i> , 2016, 18, iii166.2-iii166.	1.2	0
76	P4â€184: Shift in Cerebral PET Glucose Metabolism in Frontotemporal Dementia Linked to Chromosome 3 (FTDâ€3) from the Presymptomatic to Symtomatic Stage. <i>Alzheimer's and Dementia</i> , 2016, 12, P1090.	0.8	1
77	Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. <i>Neuro-Oncology</i> , 2016, 18, 1199-1208.	1.2	566
78	Clinical PET/MR Imaging in Dementia and Neuro-Oncology. <i>PET Clinics</i> , 2016, 11, 441-452.	3.0	32
79	Prognostic value of 18F-FET PET imaging in re-irradiation of high-grade glioma: Results of a phase I clinical trial. <i>Radiotherapy and Oncology</i> , 2016, 121, 132-137.	0.6	31
80	Acute hypoxia increases the cerebral metabolic rate â€ a magnetic resonance imaging study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2016, 36, 1046-1058.	4.3	55
81	Simultaneous evaluation of brain tumour metabolism, structure and blood volume using [18F]-fluoroethyltyrosine (FET) PET/MRI: feasibility, agreement and initial experience. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 103-112.	6.4	60
82	Use of amyloid-PET to determine cutpoints for CSF markers. <i>Neurology</i> , 2016, 86, 50-58.	1.1	54
83	Region specific optimization of continuous linear attenuation coefficients based on UTE (RESOLUTE): application to PET/MR brain imaging. <i>Physics in Medicine and Biology</i> , 2015, 60, 8047-8065.	3.0	104
84	Use of Molecular Imaging Markers of Glycolysis, Hypoxia and Proliferation (18F-FDG, 64Cu-ATSM and) Tj ETQqO O O rgBT /Overlock 10 T Monitoring. <i>Diagnostics</i> , 2015, 5, 372-382.	2.6	2
85	Positron Emission Tomography and Magnetic Resonance Imaging of the Brain in Fabry Disease: A Nationwide, Long-Time, Prospective Follow-Up. <i>PLoS ONE</i> , 2015, 10, e0143940.	2.5	18
86	Positron Emission Tomography/Magnetic Resonance Hybrid Scanner Imaging of Cerebral Blood Flow Using¹⁵O-Water Positron Emission Tomography and Arterial Spin Labeling Magnetic Resonance Imaging in Newborn Piglets. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015, 35, 1703-1710.	4.3	14
87	Automatic correction of dental artifacts in PET/MRI. <i>Journal of Medical Imaging</i> , 2015, 2, 024009.	1.5	8
88	Motion correction in simultaneous PET/MR brain imaging using sparsely sampled MR navigators: a clinically feasible tool. <i>EJNMMI Physics</i> , 2015, 2, 14.	2.7	28
89	Impact of [18F]-fluoro-ethyl-tyrosine PET imaging on target definition for radiation therapy of high-grade glioma. <i>Neuro-Oncology</i> , 2015, 17, 757-763.	1.2	58
90	Dental artifacts in the head and neck region: implications for Dixon-based attenuation correction in PET/MR. <i>EJNMMI Physics</i> , 2015, 2, 8.	2.7	18

#	ARTICLE	IF	CITATIONS
91	The Usefulness of Dynamic ^{18}F -Fluoroethyl-L-Tyrosine PET in the Clinical Evaluation of Brain Tumors in Children and Adolescents. <i>Journal of Nuclear Medicine</i> , 2015, 56, 88-92.	5.0	64
92	PET/MR attenuation correction in brain imaging using a continuous bone signal derived from UTE. <i>EJNMMI Physics</i> , 2015, 2, A39.	2.7	10
93	Early changes in perfusion of glioblastoma during radio- and chemotherapy evaluated by T1-dynamic contrast enhanced magnetic resonance imaging. <i>Acta Oncologica</i> , 2015, 54, 1521-1528.	1.8	8
94	TSPO Imaging in Glioblastoma Multiforme: A Direct Comparison Between ^{123}I -CLINDE SPECT, ^{18}F -FET PET, and Gadolinium-Enhanced MR Imaging. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1386-1390.	5.0	41
95	Brain Imaging. , 2015, , .		0
96	Computed Tomography (CT) Perfusion as an Early Predictive Marker for Treatment Response to Neoadjuvant Chemotherapy in Gastroesophageal Junction Cancer and Gastric Cancer - A Prospective Study. <i>PLoS ONE</i> , 2014, 9, e97605.	2.5	38
97	Impact of incorrect tissue classification in Dixon-based MR-AC: fat-water tissue inversion. <i>EJNMMI Physics</i> , 2014, 1, 101.	2.7	42
98	Combined PET/MR imaging in neurology: MR-based attenuation correction implies a strong spatial bias when ignoring bone. <i>NeuroImage</i> , 2014, 84, 206-216.	4.2	170
99	Sparsely sampled MR navigators as a practical tool for quality control and correction of head motion in simultaneous PET/MR. <i>EJNMMI Physics</i> , 2014, 1, A36.	2.7	3
100	Quantification and accuracy of clinical ^{11}C -PiB PET/MRI: the effect of MR-based attenuation correction. <i>EJNMMI Physics</i> , 2014, 1, A69.	2.7	1
101	Quantitation of Regional Cerebral Blood Flow Corrected for Partial Volume Effect Using ^{15}O Water and PET: II. Normal Values and Gray Matter Blood Flow Response to Visual Activation. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2000, 20, 1252-1263.	4.3	59
102	Brain Activation During Mental Transformation of Size. <i>Journal of Cognitive Neuroscience</i> , 2000, 12, 763-774.	2.3	19